GLAND2024-04-012024-06-30 GLAND2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member GLAND2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member GLAND2024-06-30 GLAND2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLAND2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543245 GLAND NOTLISTED Gland Pharma Limited Equity 2024-04-01 2025-03-31 2024-08-06 2024-07-19 INR Millions First quarter 15:00:00 16:50:00 2024-08-06 2024-08-06 Not applicable Single segment Pharmaceutical 2024-04-01 2024-06-30 Unaudited Consolidated 14017100000.00 514260000.00 14531360000.00 4616520000.00 65830000.00 960220000.00 3555270000.00 56160000.00 919620000.00 2175290000.00 12348910000.00 2182450000.00 0.00 2182450000.00 777910000.00 -33070000.00 744840000.00 0.00 1437610000.00 0.00 0.00 0.00 0.00 1437610000.00 -121950000.00 1315660000.00 1437610000.00 0.00 1315660000.00 0.00 164750000.00 1 8.73 8.73 0.00 0.00 8.73 8.73 1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2024 ( Unaudited Consolidated Financial Results ) of Gland Pharma Limited (the Holding Company or the Company ) and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the Group ) has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 6, 2024. The statutory auditors of the Company have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon. 2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the Listing requirements ). 3. The figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous year, which were subjected to a limited review. Refer the signed results uploaded for the complete notes. Other expenses 1710110000.00 Power and fuel 465180000.00 Remeasurement of defined benefit plans -6210000.00 -6210000.00 -1560000.00 Exchange differences on translation of foreign operations -117300000.00 -117300000.00 0.00